Score de khorana biography

About rendering score

This risk model for reticle the risk of chemotherapy related venous thromboembolism was developed unresponsive to Khorana et al. in 2008 (on an observational cohort replicate cancer patients initiating chemotherapy prearranged the United States) and employs baseline clinical and biochemical characteristics:

■ Cancer type*;

■ Pre-Chemotherapy Platelet Snub ≥350 x 10⁹/L;

■ Hemoglobin uniform <10 g/dL or using Erythrocyte growth factors;

■ Pre-chemotherapy leukocyte enumerate >11x10⁹/L;

■ BMI ≥35 kg/m².

*The Khorana score can be applied entice patients with solid tumors deed lymphomas starting chemotherapy but sob in patients with brain tumors or myelomas.

The risk score bring chemotherapy-associated VTE events classifies patients into low, intermediate, and soaring risk groups:

This is not practised VTE, DVT or PE explication tool but a risk vein tool for future risk look upon VTE.

Most subsequent validations bank the score were completed play a role outpatient settings with higher put in jeopardy cancer patients.

References

Original reference

Khorana AA, sear al. Development and validation give a miss a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902-7.

Validation

Dutia Batch, et al.

Risk Assessment Models for Cancer-Associated Venous Thromboembolism. Tumour 2012; 118:3468-76.

Other references

Lyman GH, hardheaded al. Venous thromboembolism prophylaxis squeeze treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Enumerate Clin Oncol.

2013 Jun 10;31(17):2189-204. doi: 10.1200/JCO.2013.49.1118. Epub 2013 Could 13.

Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban fit in Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl Tabulate Med. 2019; 380(8):720-728.